FindTrial
Sign In

ARV-471

DRUG10 trials

Sponsors

Arvinas Estrogen Receptor Inc., QuantumLeap Healthcare Collaborative, Arvinas Estrogen Receptor, Inc., Pfizer, Arvinas Inc.

Conditions

Advanced Breast CancerAngiosarcomaBreast CancerBreast NeoplasmsBreast TumorsER+Early-stage Breast CancerHER2-negative Breast Cancer

Phase 1

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Active, not recruitingNCT04072952
Arvinas Estrogen Receptor, Inc.Breast Cancer
Start: 2019-08-05End: 2026-02-27Updated: 2026-02-10
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
Active, not recruitingNCT05548127
PfizerBreast Cancer
Start: 2023-02-23End: 2026-09-01Updated: 2026-02-10
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
Active, not recruitingNCT05573555
PfizerBreast Cancer
Start: 2023-03-01End: 2026-12-30Updated: 2026-03-09
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults
CompletedNCT05652660
PfizerHealthy
Start: 2022-12-09End: 2023-03-06Updated: 2024-07-26
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults
CompletedNCT05673889
PfizerHealthy
Start: 2023-01-27End: 2023-04-19Updated: 2024-08-16
A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China
CompletedNCT05732428
PfizerBreast Cancer
Start: 2023-02-20End: 2024-11-01Updated: 2025-01-27
A Phase 1b Trial of ARV-471 in Combination with Everolimus in Patients with ER+, HER2– Advanced or Metastatic Breast Cancer
CompletedCTIS2024-513284-30-00
Arvinas Estrogen Receptor Inc.ER+, HER2– Advanced or Metastatic Breast Cancer
Start: 2023-03-22End: 2025-08-25Target: 1Updated: 2025-02-13

Phase 2

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RecruitingNCT01042379
QuantumLeap Healthcare CollaborativeAngiosarcoma, Breast Cancer, Breast Neoplasms +8
Start: 2010-03-01End: 2031-12-01Target: 5000Updated: 2026-03-13
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
CompletedNCT05549505
Arvinas Inc.Breast Cancer
Start: 2023-02-15End: 2024-07-25Updated: 2025-08-29

Phase 3

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
Active, not recruitingNCT05654623
PfizerAdvanced Breast Cancer
Start: 2023-03-03End: 2028-05-15Updated: 2026-03-18

Related Papers

Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
2026-03-25
Abstract PS3-11-10: Neoadjuvant HSP90 inhibition with ganetespib significantly improves distant relapse-free survival in I-SPY2 patients with HER2-negative breast cancer with low expression of immune genes and no DNA repair deficiency
Clinical Cancer Research2026-02-17
Abstract PS1-01-09: Real-time monitoring for drug-induced interstitial lung disease with Trastuzumab Deruxtecan and Rilvegostomig combination therapy prevents persistent, symptomatic disease: Safety insights from the I-SPY2.2 platform trial
Clinical Cancer Research2026-02-17
Abstract RF5-06: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial
Clinical Cancer Research2026-02-17
Abstract PD10-03: Subgroup analyses of VERITAC-2: A phase 3 trial of vepdegestrant, a PROTAC estrogen receptor (ER) degrader, versus fulvestrant in ER-positive/ human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)
Clinical Cancer Research2026-02-17
Abstract PS2-11-06: Quiescent-like phenotype characterizes treatment-resistant early-stage HER2-negative breast cancers and suggests novel therapeutic targets; analysis of over 2000 patients from the I-SPY2 trial
Clinical Cancer Research2026-02-17
The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants.
2026-01-19
CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.
2025-10-24
Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
Frontiers in Oncology2025-07-24
A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images
Physics in Medicine and Biology2025-07-101 citations
Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.
2025-07-012 citations
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
Breast Cancer Research2025-06-233 citations
Abstract P4-12-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results
Clinical Cancer Research2025-06-134 citations
Abstract P4-08-13: Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination With Cyclin-Dependent Kinase (CDK)4/6 Inhibitors and Everolimus
Clinical Cancer Research2025-06-132 citations
Abstract P2-01-23: A 140-gene Machine Learning Classifier Predicts Survival and Response to Chemotherapy and Immunotherapy in 2500 TNBC
Clinical Cancer Research2025-06-13
Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: Results of the global, randomized, phase 3 VERITAC-2 study.
Journal of Clinical Oncology2025-06-047 citations
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
New England Journal of Medicine2025-05-3145 citations
Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
Journal of Clinical Oncology2025-05-283 citations
Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).
Journal of Clinical Oncology2025-05-28
I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).
Journal of Clinical Oncology2025-05-28

92 more papers not shown